Protein Glycosylation as Biomarkers in Gynecologic Cancers
Gynecologic cancers are the leading cause of death in women. Endometrial, ovarian, and cervical cancer are the three main types of gynecologic cancers. Poor prognoses and high mortality rates of advanced-stage cancer are still challenges of all three types. Diagnostic tools for early cancer detectio...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/12/3177 |
| _version_ | 1797460633630801920 |
|---|---|
| author | Hung Shen Chia-Yi Lee Chi-Hau Chen |
| author_facet | Hung Shen Chia-Yi Lee Chi-Hau Chen |
| author_sort | Hung Shen |
| collection | DOAJ |
| description | Gynecologic cancers are the leading cause of death in women. Endometrial, ovarian, and cervical cancer are the three main types of gynecologic cancers. Poor prognoses and high mortality rates of advanced-stage cancer are still challenges of all three types. Diagnostic tools for early cancer detection could be the cornerstone for further cancer treatment and prevention. Glycosylation plays a vital role in cell proliferation, adhesion, motility, and angiogenesis, and is aberrantly expressed in cancer cells. Alterations of glycosylation may represent promising biomarkers with potential diagnostic and monitoring applications, as well as disease prognosis. Many glycosylated biomarkers, including glycoprotein, glycan, and enzyme, were discovered and well-studied for application in gynecologic cancers. Some of them have been developed as targets for cancer treatment. The use of certain biomarkers for diagnostics and monitoring of gynecologic cancers has clinical advantages, as it is quantitative, comparable, convenient, and inexpensive. However, one of the single markers have sufficient sensitivity for the screening of gynecologic cancers. In this review, we introduced the details of glycosylation and the current application of glycosylated biomarkers in these three cancers. Moreover, we also reviewed the different roles of each biomarker in other cancers and aimed to understand these glycosylated biomarkers comprehensively. |
| first_indexed | 2024-03-09T17:08:47Z |
| format | Article |
| id | doaj.art-db52c96d4e9748f9b4493a1f793e639d |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T17:08:47Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-db52c96d4e9748f9b4493a1f793e639d2023-11-24T14:20:02ZengMDPI AGDiagnostics2075-44182022-12-011212317710.3390/diagnostics12123177Protein Glycosylation as Biomarkers in Gynecologic CancersHung Shen0Chia-Yi Lee1Chi-Hau Chen2Department of Obstetrics and Gynecology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City 300, TaiwanDepartment of Obstetrics and Gynecology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City 300, TaiwanDepartment of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei 100, TaiwanGynecologic cancers are the leading cause of death in women. Endometrial, ovarian, and cervical cancer are the three main types of gynecologic cancers. Poor prognoses and high mortality rates of advanced-stage cancer are still challenges of all three types. Diagnostic tools for early cancer detection could be the cornerstone for further cancer treatment and prevention. Glycosylation plays a vital role in cell proliferation, adhesion, motility, and angiogenesis, and is aberrantly expressed in cancer cells. Alterations of glycosylation may represent promising biomarkers with potential diagnostic and monitoring applications, as well as disease prognosis. Many glycosylated biomarkers, including glycoprotein, glycan, and enzyme, were discovered and well-studied for application in gynecologic cancers. Some of them have been developed as targets for cancer treatment. The use of certain biomarkers for diagnostics and monitoring of gynecologic cancers has clinical advantages, as it is quantitative, comparable, convenient, and inexpensive. However, one of the single markers have sufficient sensitivity for the screening of gynecologic cancers. In this review, we introduced the details of glycosylation and the current application of glycosylated biomarkers in these three cancers. Moreover, we also reviewed the different roles of each biomarker in other cancers and aimed to understand these glycosylated biomarkers comprehensively.https://www.mdpi.com/2075-4418/12/12/3177glycosylationovarian cancerendometrial cancercervical cancerbiomarker |
| spellingShingle | Hung Shen Chia-Yi Lee Chi-Hau Chen Protein Glycosylation as Biomarkers in Gynecologic Cancers Diagnostics glycosylation ovarian cancer endometrial cancer cervical cancer biomarker |
| title | Protein Glycosylation as Biomarkers in Gynecologic Cancers |
| title_full | Protein Glycosylation as Biomarkers in Gynecologic Cancers |
| title_fullStr | Protein Glycosylation as Biomarkers in Gynecologic Cancers |
| title_full_unstemmed | Protein Glycosylation as Biomarkers in Gynecologic Cancers |
| title_short | Protein Glycosylation as Biomarkers in Gynecologic Cancers |
| title_sort | protein glycosylation as biomarkers in gynecologic cancers |
| topic | glycosylation ovarian cancer endometrial cancer cervical cancer biomarker |
| url | https://www.mdpi.com/2075-4418/12/12/3177 |
| work_keys_str_mv | AT hungshen proteinglycosylationasbiomarkersingynecologiccancers AT chiayilee proteinglycosylationasbiomarkersingynecologiccancers AT chihauchen proteinglycosylationasbiomarkersingynecologiccancers |